Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

(Amendment No. 4)

 

Under the Securities Exchange Act of 1934

 

SEMLER SCIENTIFIC, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

81684M 104

(CUSIP Number)

Yvan-Claude Pierre, Esq.

Marianne C. Sarrazin, Esq.

Cooley LLP

55 Hudson Yards

New York, New York 10001-2157

Telephone: (212) 479-6000

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

May 3, 2019

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

 

 

SCHEDULE 13D

 

CUSIP No. 81684M 104

1	NAMES OF REPORTING PERSONS   Douglas Murphy-Chutorian, M.D.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a) ¨           (b) ¨
3	SEC USE ONLY
4	SOURCE OF FUNDS*   PF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)         ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION   United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER   652,552 shares
	8	SHARED VOTING POWER   234,243 shares
	9	SOLE DISPOSITIVE POWER   652,552 shares
	10	SHARED DISPOSITIVE POWER   234,243 shares

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   886,795 shares
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*   ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)   12.4%*
14	TYPE OF REPORTING PERSON*   IN

 

*

Based upon an aggregate of 6,331,147 shares of the Issuer’s (as defined below) common stock outstanding as of May 1, 2019 as reported in the Issuer’s Quarterly Report on Form 10-Q/A filed on May 7, 2019.

 

 

Item 1.

Security and Issuer

 

The equity securities covered by this Schedule 13D (Amendment No. 4) are shares of common stock, $0.001 par value, of Semler Scientific, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 911 Bern Court, Suite 110, San Jose, CA 95112.

 

Item 2.

Identity and Background

 

This statement is filed by Douglas Murphy-Chutorian, M.D., a U.S. citizen (the “Reporting Person”). The Reporting Person’s business address is the same as that of the Issuer, 911 Bern Court, Suite 110, San Jose, CA 95112, and his present principal occupation is serving as Chief Executive Officer and a Director of the Issuer.

 

The Reporting Person has not, during the last five years, (a) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.

Source and Amount of Funds or Other Consideration

 

The information contained in Item 5 is incorporated by reference into this Item 3.

 

Item 4.

Purpose of Transaction.

 

The information contained in Item 5 is incorporated by reference into this Item 4.

 

Except as set forth or incorporated by reference in this Item 4, the Reporting Person has no present plans or proposals that relate to, or that would result in, any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

 

Item 5.

Interest in Securities of the Issuer.

 

On May 3, 2019, the Reporting Person sold to the Issuer a warrant to purchase 65,542 shares of the Issuer’s common stock, originally issued July 31, 2012, with an original exercise price of $4.50 per share, for a net sale dollar amount of $2,687,222.00 (or an effective price per share of $41.00, representing the difference between the last sale price for a share of the Issuer’s common stock on May 3, 2019 and the exercise price per share of the warrant).

 

Following the sale of the warrant back to the Issuer, the Reporting Person is the beneficial owner of an aggregate of 886,795 shares of the Issuer’s common stock (approximately 12.4% based on 6,331,147 shares issued and outstanding on May 1, 2019). Other than (x) the 63,571 shares of common stock and (y) warrants to acquire an aggregate of 170,672 shares of common stock held in the Reporting Person’s family trust, over which he shares voting and investment control with his spouse, the Reporting Person has sole voting and investment control over such shares. Such beneficial ownership includes: (i) warrants to purchase 25,000 shares of the Issuer’s common stock at $2.00 per share, which warrants expire July 31, 2023; (ii) warrants to purchase 16,875 shares of the Issuer’s common stock at $4.00 per share, which warrants expire July 31, 2023; (iii) warrants to purchase 89,890 shares of the Issuer’s common stock at $4.50 per share, which warrants expire July 31, 2023; (iv) warrants to purchase 38,907 shares of the Issuer’s common stock at $4.50 per share, which warrants expire July 31, 2023 and (v) an aggregate of 652,552 shares subject to options that are currently exercisable or exercisable within 60 days of May 6, 2019.

 

 

Depending upon future evaluations of the business prospects of the Issuer and upon other developments, including, but not limited to, general economic and business conditions and stock market conditions, the Reporting Person may purchase additional equity or other securities of the Issuer or dispose of some or all of his holdings in the open market, in public offerings, in privately negotiated transactions or in other transactions, including future dispositions back to the Issuer, or in any combination of the foregoing, subject to the Issuer’s insider trading policy and relevant applicable securities laws and regulations.

 

Other than the sale back to the Issuer of the warrant as described in this Item 5, the Reporting Person has not effected any transaction in the Issuer’s common stock during the 60 days prior to the date of this Schedule 13D (Amendment No. 4).

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

None.

 

Item 7.

Materials to be Filed as Exhibits

 

 

SIGNATURE

 

After reasonable inquiry and to the best of such Reporting Person’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: May 7, 2019

 

	/s/ Douglas Murphy-Chutorian, M.D.
	DOUGLAS MURPHY-CHUTORIAN, M.D.